---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-346856"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2026-08-12T20:10:19+00:00"
generated_at: "2026-08-12T20:11:21.787204+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Kura Q2: KOMZIFTI revenue $9.1M, majority share in NPM1-m AML menin class

## Summary
- KOMZIFTI net product revenue $9.1M, up 57% QoQ; ~115 new patient starts, up 35% QoQ.
- Achieved majority share of new patient starts in R/R NPM1-m AML menin inhibitor class.
- EHA 2026 KOMET-007: CRc 96% (NPM1-m) and 90% (KMT2A-r) with 600mg ziftomenib+7+3; 12-mo OS 94%/71%.
- Net loss $68.3M; cash $519.0M plus $180M anticipated Kyowa Kirin payments fund through 2028 pivotal readout.
- Darlifarnib combo data: 67% ORR pancreatic, 50% NSCLC in KRAS G12C; ccRCC ORR up to 50%.

## SEC filing metadata
- accession: 0001193125-26-346856
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2026-08-12T20:10:19+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000119312526346856/0001193125-26-346856-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000119312526346856/kura-20260812.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-346856
- JSON: https://secwatch.observer/filing/0001193125-26-346856.json
- Plain text: https://secwatch.observer/filing/0001193125-26-346856.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.